A Phase 2/3 interventional study of Placebo group and JS1-1-01 low-dose group in Depression, sponsored by Tasly Pharmaceutical Group Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.
Among the 358 studies in Depression with a site in China, this one is the 106th largest by planned enrollment of the 284 interventional ones that give a count, is one of 38 that started in 2026, is one of 6 in phase 2/3, reaches primary completion later than 79 of the 137 other live ones, and was the 328th registered.
8,602 studies on the registry are indexed under Depression; 1,735 are open to participants now.
Browse Depression studies →119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Australia and 12 more countries
Ages 18–75
Xidian University · Sites in China
Ages 18–30 · Healthy volunteers
Peking University · Sites in China
Ages 18–50
Tianjin Medical University · Sites in China
Ages 18–90 · Healthy volunteers
Moon (Guangzhou) Biotechnology Co., Ltd. · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,099 Depression studies recruiting now, 474 (43%) set no upper age limit and 524 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
358 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 20 · Phase 3 13 · Phase 4 24
First in 2006; this study’s year is marked. 38 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 81 across 7,083 interventional studies indexed under Depression.
Median enrollment 129 across the 284 interventional studies, 306 across the 74 observational. Of the 140 that completed or were terminated, 9 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 358 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tasly Pharmaceutical Group Co., Ltd, one of the names counted as China Resources Pharmaceutical Group Limited. Under that name alone:
Tasly Pharmaceutical Group Co., Ltd is the lead sponsor of 32 studies on the registry; 17 are open to participants now.
China Resources Pharmaceutical Group Limited has 2 studies filed under Depression — fewer than ten, so there is no comparison to draw.
43 of the studies in Depression with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485595Phase 3Tasly Pharmaceutical Group Co., LtdA Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression | 2026-12-31 |
| NCT07738809Capital University of Physical Education and Sports, ChinaEffects of Exercise Intervention on Sleep Quality and Emotional Problems in College Students With Depressive Symptoms | 2026-11 |
| NCT07179913The First Hospital of Jilin UniversityThe Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression | 2026-11-20 |
| NCT07247968Min SuSubanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study | 2026-11-20 |
| NCT07282366Jian-Jun OuVideo Intervention to Reduce Depression-related Stigma Among Adolescents | 2026-11-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 358 studies in Depression with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo group
Drug: JS1-1-01 low-dose group
Drug: JS1-1-01 high-dose group
(2 of 50 mg JS1-1-01 placebo tablets+1 of 75 mg JS1-1-01 placebo tablets)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
Also known as: JS1-1-01 placebo tablet
(2 of 50 mg JS1-1-01 placebo tablets+1 of 75 mg JS1-1-01 tablets)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
Also known as: JS1-1-01 tablet ; JS1-1-01 placebo tablet
(2 of 50 mg JS1-1-01 tablets+1 of 75 mg JS1-1-01 placebo tablets)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
Also known as: JS1-1-01 tablet ; JS1-1-01 placebo tablet
The change in MADRS total score from baseline
There are a total of 10 projects in Montgomery-Asberg Depression Rating Scale(MADRS), each with a 7-point scoring system ranging from 0 to 6 points. The higher the score, the more severe the degree of depression.
Time frame: 8 weeks
The change in HAMD-17 total score from baseline
There are a total of 17 projects in Hamilton Depression Scale-17(HAMD-17). Scores are distributed on a scale of 0 to 53. A score above 24 indicates severe depression, a score of 17 indicates moderate depression, and a score below 7 indicates no depressive symptoms.
Time frame: 8 weeks
The effective rate of MADRS
The effective definition of MADRS is that the reduction rate of MADRS score relative to baseline is ≥ 50%
Time frame: 8 weeks
The effective rate of HAMD-17
The effective definition of HAMD-17 is that the reduction rate of HAMD-17 score relative to baseline is ≥ 50%.
Time frame: 8 weeks
The response rate of MADRS
The response definition of MADRS is that the score ≤ 12 points.
Time frame: 8 weeks
The response rate of HAMD-17
he response definition of HAMD-17 is that the score ≤ 7 points.
Time frame: 8 weeks
The change in MADRS Single item score from baseline
Each single item has a 7-point scoring system ranging from 0 to 6 points. The higher the score, the more severe the degree of depression.
Time frame: 8 weeks
The change in HAMD-17 factor score from baseline
1. Items scored 0-4 (5-point scale, 8 items) Depressed mood, feelings of guilt, suicide, work and interests, retardation, agitation, psychic anxiety, somatic anxiety 2. Items scored 0-2 (3-point scale, 9 items) Difficulty falling asleep, insomnia during sleep, early awakening, gastrointestinal symptoms, general somatic symptoms, genital symptoms, hypochondriasis, weight loss, insight. The higher the score, the more severe the degree of depression.
Time frame: 8 weeks
The change in CGI-S total score from baseline
Perform the Clinical Global Impression Scale (CGI-S) score from Visit 1 to Visit 7,The highest score is 7 points, and the higher the score, the more severe the condition will be.
Time frame: 8 weeks
Proportion of participants with a CGI-S score of 1/2
Perform the Clinical Global Impression Scale (CGI-I) score from Visit 3 to Visit 7.The highest score is 7 points, and the higher the score, the more severe the condition will be.
Time frame: 8 weeks
Proportion of CGI-I Scores on the Clinical Global Impression Scale
Perform the Clinical Global Impression Scale (CGI-I) score from Visit 3 to Visit 7.The highest score is 7 points, and the higher the score, the more severe the condition will be.
Time frame: 8 weeks
The change in HAMA total score from baseline
There are a total of 14 projects in Hamilton Scale(HAMA).The total score ranges from a minimum of 0 to a maximum of 56. The higher the score, the more severe the anxiety.
Time frame: 8 weeks
The change in ISI total score from baseline
There are a total of 7 projects in Insomnia Severity Index(ISI) . The total score ranges from a minimum of 0 to a maximum of 28. The higher the score, the more severe the degree of insomnia.
Time frame: 8 weeks
The change in DSST total score from baseline
Participants are required to match symbols with numbers according to the coding key as many as possible within 90 seconds. One point is awarded for each correct matching item; the first 10 sample items are unscored and not timed. The total score ranges from a minimum of 0 to a maximum of 90. Higher scores indicate better cognitive processing speed and represent a superior outcome. The lower the score, the worse of the cognitive function.
Time frame: 8 weeks
The change in PDQ-D total score from baseline
The total score ranges from a minimum of 0 to a maximum of 80. The higher the score, the worse of the cognitive function.
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.
Of 32 phase 2/3 interventional studies under Depression, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 56. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tasly Pharmaceutical Group Co., Ltd →